MedTrace Logo

Biodistribution and Pharmacokinetics of Pretomanid in Tuberculosis Patients Using 18F-Pretomanid PET

NCT05609552 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2025-12-12

No results posted yet for this study

Summary

This is an observational study that will examine the pretomanid pharmacokinetics (PK) in tuberculosis (TB) patients. Dynamic 18F-pretomanid PET/CT will be performed after intravenous injection of 18F-pretomanid to determine multi-compartment, noninvasive determination of pretomanid PK in TB patients.

Conditions

Interventions

COMBINATION_PRODUCT

18F-Pretomanid PET/CT

A bolus of less than or equal to 10 mCi (370 MBq) of 18F-pretomanid will be injected into the intravenous line by slow IV push. Immediately after administration of 18F-pretomanid, dynamic PET acquisition will take place.

Sponsors & Collaborators

Principal Investigators

  • Sanjay K Jain, M.D. · Johns Hopkins University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-22
Primary Completion
2025-10-28
Completion
2025-10-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05609552 on ClinicalTrials.gov